Post/November 10, 2026Silevertinib heads for a Phase 3 trial built around lung cancer that has spread to the brainBlack Diamond plans a silevertinib Phase 3 trial in 2027 for EGFR lung cancer with brain metastases, after an FDA meeting and new Phase 2 data.HNHealthcare News·November 10, 2026
Post/November 10, 2026NuNerve's MND drug NUN-004 faces its first placebo-controlled test after early signs of stabilising diseaseNuNerve's NUN-004 Phase 2 trial will test the MND drug against placebo in 75 people across six Australian sites, after a small open-label first study.HNHealthcare News·November 10, 2026
